Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Narcisi

Showing results (11-20 of 185) with videos related to

Pageof 19
Sort By:
Dermatology Practical & Conceptual|August 12, 2024
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% OintmentMario Valenti, Matteo Bianco, Alessandra Narcisi, et al.
Journal of Personalized Medicine|February 23, 2024
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective StudyGiovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, et al.
Dermatologic Therapy|October 21, 2022
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case reportMario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The International Journal of Developmental Biology|September 17, 2015
Programmed cell death in the skinAntonio Costanzo, Francesca Fausti, Giulia Spallone, et al.
Dermatology Practical & Conceptual|August 9, 2024
Non-invasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal MicroscopyFrancesco Piscazzi, Chiara Franceschini, Alessandra Narcisi, et al.
Dermatology Reports|April 16, 2024
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeksLuciano Ibba, Luigi Gargiulo, Giulia Pavia, et al.
The Journal of Dermatological Treatment|February 6, 2026
Dose escalation and personalization in atopic dermatitis: reply to the real-world study by Demirbaş et al. "<i>Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.</i>"Luigi Gargiulo, Matteo Bianco, Luciano Ibba, et al.
Dermatology Practical & Conceptual|May 17, 2023
Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two CasesLuigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia, et al.
Dermatology Practical & Conceptual|August 9, 2023
Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case SeriesLuigi Gargiulo, Carlo Alberto Vignoli, Andrea Cortese, et al.
Expert Opinion on Drug Safety|March 24, 2025
An updated safety review of Hidradenitis Suppurativa treatment optionsRuggero Cascio Ingurgio, Luciano Ibba, Angela Alfano, et al.
Pageof 19

Showing results (11-20 of 185) with videos related to

Sort By:
Pageof 19
Dermatology Practical & Conceptual|August 12, 2024
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% OintmentMario Valenti, Matteo Bianco, Alessandra Narcisi, et al.
Journal of Personalized Medicine|February 23, 2024
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective StudyGiovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, et al.
Dermatologic Therapy|October 21, 2022
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case reportMario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The International Journal of Developmental Biology|September 17, 2015
Programmed cell death in the skinAntonio Costanzo, Francesca Fausti, Giulia Spallone, et al.
Dermatology Practical & Conceptual|August 9, 2024
Non-invasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal MicroscopyFrancesco Piscazzi, Chiara Franceschini, Alessandra Narcisi, et al.
Dermatology Reports|April 16, 2024
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeksLuciano Ibba, Luigi Gargiulo, Giulia Pavia, et al.
The Journal of Dermatological Treatment|February 6, 2026
Dose escalation and personalization in atopic dermatitis: reply to the real-world study by Demirbaş et al. "<i>Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.</i>"Luigi Gargiulo, Matteo Bianco, Luciano Ibba, et al.
Dermatology Practical & Conceptual|May 17, 2023
Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two CasesLuigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia, et al.
Dermatology Practical & Conceptual|August 9, 2023
Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case SeriesLuigi Gargiulo, Carlo Alberto Vignoli, Andrea Cortese, et al.
Expert Opinion on Drug Safety|March 24, 2025
An updated safety review of Hidradenitis Suppurativa treatment optionsRuggero Cascio Ingurgio, Luciano Ibba, Angela Alfano, et al.
Pageof 19